share_log

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K: Gsk on track to deliver 2024 outlooks with further good progress made in r&d

6-K:葛兰素史克有望实现2024年愿景,研发方面取得进一步良好进展
美股SEC公告 ·  2024/10/30 23:27

Moomoo AI 已提取核心信息

GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSK reported Q3 2024 total sales of £8.0 billion, down 2% AER but up 2% CER, driven by strong Specialty Medicines performance offsetting lower Vaccines sales. Core operating profit grew 5% CER to £2.8 billion, reflecting favorable product mix and cost management.Total operating profit fell 86% to £189 million after a £1.8 billion charge for Zantac settlement, covering 93% of US state court cases. Core EPS increased 5% CER to 49.7p, while reported EPS was -1.4p. The company reached agreements to resolve approximately 80,000 Zantac cases for up to $2.2 billion.GSK confirmed its full-year 2024 guidance, expecting to deliver around the middle of ranges: 7-9% sales growth, 11-13% core operating profit growth, and 10-12% core EPS growth at CER. Q3 dividend of 15p declared, with full-year dividend expected at 60p. The company made further R&D progress with 11 positive phase III trials reported year-to-date.
GSk报告2024财年第三季度总销售额为80亿英镑,同比下降2%(按实际汇率计算),但按恒定汇率增长2%,主要得益于强劲的特殊药物表现,抵消了疫苗销售的下降。核心营业利润按恒定汇率增长5%,达28亿英镑,反映了有利的产品组合和成本管理。总营业利润下降86%,至18900万英镑,因Zantac和解计入了18亿英镑的费用,涵盖了93%的美国州法院案件。核心每股收益按恒定汇率增加5%,至49.7便士,而报告每股收益为-1.4便士。该公司已达成协议,解决大约80,000个Zantac案件,达成最高22亿美金的和解。GSk确认了2024财年的全年指引,预计销售增长和核心营业利润增长均约在范围中间:销售增长7-9%,核心营业利润增长11-13%,核心每股收益增长10-12%(按恒定汇率计算)。宣布第三季度股息为15便士,全年股息预计为60便士。该公司在研发方面取得了进一步进展,今年迄今报告了11个积极的第III阶段临床试验。
GSk报告2024财年第三季度总销售额为80亿英镑,同比下降2%(按实际汇率计算),但按恒定汇率增长2%,主要得益于强劲的特殊药物表现,抵消了疫苗销售的下降。核心营业利润按恒定汇率增长5%,达28亿英镑,反映了有利的产品组合和成本管理。总营业利润下降86%,至18900万英镑,因Zantac和解计入了18亿英镑的费用,涵盖了93%的美国州法院案件。核心每股收益按恒定汇率增加5%,至49.7便士,而报告每股收益为-1.4便士。该公司已达成协议,解决大约80,000个Zantac案件,达成最高22亿美金的和解。GSk确认了2024财年的全年指引,预计销售增长和核心营业利润增长均约在范围中间:销售增长7-9%,核心营业利润增长11-13%,核心每股收益增长10-12%(按恒定汇率计算)。宣布第三季度股息为15便士,全年股息预计为60便士。该公司在研发方面取得了进一步进展,今年迄今报告了11个积极的第III阶段临床试验。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息